A Psilocybin Study in Post-Lyme Illness, and the Comparison It Couldn't Make
There is no established treatment for post-treatment Lyme disease. That sentence is the reason a study like this one gets run at all, and it is also the reason the results deserve careful interpretation rather than excitement.
Roughly 10 to 20 percent of people treated for Lyme disease go on to develop post-treatment Lyme disease, or PTLD, which is a chronic pattern of fatigue, pain, cognitive difficulty, mood disturbance, and reduced quality of life that persists after the antibiotics are finished [1]. A team at Johns Hopkins published a pilot study in February testing whether psilocybin might help.
What the Hopkins pilot study found
Twenty adults with well-characterized PTLD completed an eight-week program [1]. Eleven were women and nine were men, mean age 44, with a median illness duration of 5.7 years. The intervention included two psilocybin sessions with psychological support: 15 mg in week four, then 15 or 25 mg in week six. I am describing what was administered under a research protocol with medical monitoring, which is not a dose recommendation.
The reported improvements were substantial. At six months, general symptom burden on the GSQ-30 had decreased 40 percent from baseline (p < .001, Cohen's d = -1.22). Quality of life improved on both the mental and physical component scores of the SF-36, each by 13 percent. Secondary measures of mood, fatigue, sleep quality, and pain all improved significantly and remained improved through six months.
There were no serious adverse events related to the intervention. The common events attributed to psilocybin were transient high blood pressure (90 percent of participants), headache (65 percent), rapid heart rate (35 percent), pain (20 percent), and fatigue (15 percent).
The design is the part that needs care. This was an open-label, single-arm pilot study. Open-label means everyone knew what they were taking. Single-arm means there was no comparison group at all: every participant received psilocybin, and nobody received a placebo, psychological support alone, or simple observation over the same eight weeks. The authors call the findings preliminary and say they warrant further investigation, which is an accurate description of what this kind of study can produce.
What placebo-controlled psilocybin trials have found
Why is a missing comparison group such a problem here? Because when psilocybin has been tested against a placebo, the difference between them has sometimes failed to reach significance.
In an exploratory placebo-controlled trial in major depressive disorder, participants received placebo and then psilocybin four weeks later, with enhanced blinding procedures and a structured course of psychotherapy around both [2]. Depression and anxiety improved significantly after both conditions, and there was no statistically significant difference in the degree of change between them. Effect sizes were larger after psilocybin, and rates of response (66.7 percent) and remission (46.7 percent) following psilocybin were high. Nevertheless, the placebo condition also produced substantial improvement. The authors describe their own results as showing the complex interplay between expectancy, therapy effects, and drug effects in psychedelic-assisted research.
There is a serious counterargument, and it deserves airing. The authors of a 2023 paper argue that unblinding does not automatically invalidate a psychedelic trial, seeing as the subjective experience is inseparable from the proposed mechanism, and that the link between subjective effects and efficacy is weaker in conventional antidepressant trials than critics assume [3]. That argument is a reasonable one. It is also relevant that all four authors were employed by COMPASS Pathfinder, a company developing psilocybin therapy, which the paper discloses.
One more piece of context explains why this line of research exists. A 2024 systematic review of eight randomized trials of antibiotic treatment for post-treatment Lyme symptoms found no statistically significant benefit over placebo for quality of life, cognition, or depression, inconsistent results for fatigue, and significantly more adverse events with antibiotics [4]. The authors' conclusion is blunt: patients with suspected PTLD should not be treated with antibiotics. The intervention people are most often offered does not work.
What post-infectious illness looks like over time
Post-infectious illness is the part of this I see most in practice, and the persistence is not in anyone's imagination.
Here is how long it can last after a different infection. After a waterborne Giardia outbreak in Bergen, Norway, 44.9 percent of exposed people without asthma reported chronic fatigue three years later, compared with 10.7 percent of controls [5]. At six years, functional gastrointestinal and fatigue syndromes were still measurably more common in the exposed group [6]. Both studies are questionnaire-based and had an uneven response rate between groups, which will have inflated the exposed-group figures by an unknown amount. Even discounted for that, a single treated infection was still affecting people's health six years later.
That is the kind of illness the Hopkins team studied. What stands out in the Hopkins result is which measures changed. Mood, fatigue, sleep, pain, and overall quality of life improved together. In a condition with no disease-modifying treatment, an intervention that changes a person's relationship to a symptom load is not a trivial thing, whether or not it alters the underlying biology. Whether psilocybin produced that, or whether eight weeks of structured attention and skilled psychological support produced it, is precisely the question this design cannot answer.
Psilocybin is a Schedule I controlled substance. I do not prescribe it, it is not available through my practice, and nothing here is a suggestion to seek it out. The participants received pharmaceutical-grade doses in a research setting, with medical monitoring and trained support around every session, and 90 percent of them had a transient rise in blood pressure. That combination of screening, supervision, and monitoring cannot be reproduced on your own, and the risks of attempting it are not theoretical.
For anyone living with post-Lyme illness right now
The antibiotic finding is the one you can act on today. If you are still being offered repeat or prolonged antibiotic courses for persistent post-Lyme symptoms, the systematic review found no benefit over placebo and significantly more adverse events with antibiotics [4]. That is a specific and current thing to raise with the provider managing your care.
Research on psilocybin for this condition is at the pilot stage: twenty people, no control group, a single center. If it interests you, the appropriate route is a registered clinical trial rather than any informal arrangement, and ClinicalTrials.gov is where those are listed.
Symptom-directed care is still care. Sleep, pain, mood, and fatigue were measured in this study because they are what make this illness hard to live with, and each has approaches that do not require waiting for a psychedelic trial to report results.
If your symptoms have been dismissed as psychological, notice what the researchers assumed when they designed this study, rather than what the study might seem to imply. A major academic center studied this population because the symptom burden is well documented and the illness is well characterized. An intervention that acts on the brain is not evidence that the problem was imaginary.
References
Primary research located and verified via PubMed.
Garcia-Romeu A, Naudé GP, Rebman AW, So S, Yaffe A, Geithner I, Kozero EA, Yang T, Soloski MJ, Aucott JN. Pilot study of psilocybin in patients with post-treatment Lyme disease. Sci Rep. 2026;16(1). PMID 41741501. https://doi.org/10.1038/s41598-026-38091-9 (ClinicalTrials.gov NCT05305105)
Sloshower J, Skosnik PD, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D'Souza DC. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. J Psychopharmacol. 2023;37(7):698-706. PMID 36938991. https://doi.org/10.1177/02698811231154852
Goodwin GM, Croal M, Marwood L, Malievskaia E. Unblinding and demand characteristics in the treatment of depression. J Affect Disord. 2023;328:1-5. PMID 36781142. https://doi.org/10.1016/j.jad.2023.02.030 (all authors employed by COMPASS Pathfinder Ltd, a psilocybin therapy developer; disclosed in the paper)
Dersch R, Torbahn G, Rauer S. Treatment of post-treatment Lyme disease symptoms — a systematic review. Eur J Neurol. 2024;31(7):e16293. PMID 38606630. https://doi.org/10.1111/ene.16293
Hanevik K, et al. The impact of atopic disease on the risk of post-infectious fatigue and irritable bowel syndrome 3 years after Giardia infection: a historic cohort study. Scand J Gastroenterol. 2012. PMID 22746290. https://doi.org/10.3109/00365521.2012.696681 (held in the Yggdrasil Abstract Library)
Hanevik K, et al. The relationship between irritable bowel syndrome, functional dyspepsia, chronic fatigue and overactive bladder syndrome: a controlled study 6 years after acute gastrointestinal infection. BMC Gastroenterol. 2015. PMID 26058591. https://doi.org/10.1186/s12876-015-0296-0 (held in the Yggdrasil Abstract Library)
A note before you go
This article is educational and is not medical advice. It describes research conducted under a controlled protocol with medical screening and monitoring, and it is not a recommendation to pursue any of it independently. Psilocybin is a Schedule I controlled substance and is not part of naturopathic scope of practice. If you are living with post-treatment Lyme disease, decisions about your care belong with the clinicians who know your history, and if you are struggling with your mood, please reach out to a licensed provider rather than managing it alone.
If this resonates with what you're experiencing and you'd like to explore a naturopathic approach, book a consultation with our clinic.
Comments